for Tardive Dyskinesia in Adults

About the clinical studies*

AUSTEDO® (deutetrabenazine) tablets were studied in a diverse population with the goal of identifying the change in uncontrollable movements—as measured by the Abnormal Involuntary Movement Scale (AIMS) total score—from the beginning to the end of the 12-week studies.

A closer look at the data

98%

of people in one study were taking at least one mental health medication, including:

Antidepressants:

  • 54%

    ANTIDEPRESSANTS
    AT BASELINE

Antipsychotics:

  • 62%

    ATYPICAL ANTIPSYCHOTICS

  • 14%

    TYPICAL OR COMBINATION ANTIPSYCHOTICS

  • 24%

    NO ANTIPSYCHOTICS AT BASELINE

Sex

52 percent of women and 48 percent of men.

48%

48% MALE

52%

52% FEMALE

Underlying mental
health conditions

50 percent have schizophrenia, 19 percent have depression, 17 percent have bipolar disorder, 10 percent have schizoaffective disorder, and 4 percent have other.

10%

10% SCHIZOAFFECTIVE
DISORDER

17%

17% BIPOLAR DISORDER

19%

19% DEPRESSION

4%

4% OTHER

50%

50% SCHIZOPHRENIA

*Once-daily AUSTEDO XR® (deutetrabenazine) extended-release tablets contain the same active ingredient as twice-daily AUSTEDO. Data on this page is based on twice-daily dosing.

Throughout both studies, people continued with their mental health medications while taking twice-
daily AUSTEDO to reduce Tardive Dyskinesia (TD) body movements.

You Don't need to choose between maintaining
your mental health or treating TD

Cherian Karunapuzha, neurologist, sitting in chair.

Watch professionals discuss
treating TD with AUSTEDO

Patients can continue on their current psychiatric medication regimen along with the addition of AUSTEDO.

Cherian Karunapuzha

Neurologist, Oklahoma City, OK

Stay in the know

Sign up for TD treatment tips, information about patient
support, and educational resources.

Sign up now
Sign up for Tardive Dyskinesia treatment tips, information about patient support, and educational resources.
Allyable tool icon